Cargando…

Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification

Checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade. Nevertheless, these are only beneficial for a small proportion of cancer patients. Important prognosticators for response to immunotherapy are the mutation burden of tumours as well as the quality and quanti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ijsselsteijn, Marieke E, Brouwer, Thomas P, Abdulrahman, Ziena, Reidy, Eileen, Ramalheiro, Ana, Heeren, A Marijne, Vahrmeijer, Alexander, Jordanova, Ekaterina S, de Miranda, Noel FCC
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317065/
https://www.ncbi.nlm.nih.gov/pubmed/30191683
http://dx.doi.org/10.1002/cjp2.113
_version_ 1783384677100290048
author Ijsselsteijn, Marieke E
Brouwer, Thomas P
Abdulrahman, Ziena
Reidy, Eileen
Ramalheiro, Ana
Heeren, A Marijne
Vahrmeijer, Alexander
Jordanova, Ekaterina S
de Miranda, Noel FCC
author_facet Ijsselsteijn, Marieke E
Brouwer, Thomas P
Abdulrahman, Ziena
Reidy, Eileen
Ramalheiro, Ana
Heeren, A Marijne
Vahrmeijer, Alexander
Jordanova, Ekaterina S
de Miranda, Noel FCC
author_sort Ijsselsteijn, Marieke E
collection PubMed
description Checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade. Nevertheless, these are only beneficial for a small proportion of cancer patients. Important prognosticators for response to immunotherapy are the mutation burden of tumours as well as the quality and quantity of tumour‐infiltrating immune cells. High‐throughput multiplex immunophenotyping technologies have a central role in deciphering the complexity of anti‐tumour immune responses. Current techniques for the immunophenotyping of solid tumours are held back by the lack of spatial context, limitations in the number of targets that can be visualised simultaneously, and/or cumbersome protocols. We developed a tyramide signal amplification‐free method for the simultaneous detection of seven cellular targets by immunofluorescence. This method overcomes limitations posed by most widespread techniques and provides a unique tool for extensive phenotyping by multispectral fluorescence microscopy. Furthermore, it can be easily implemented as a high‐throughput technology for validation of discovery sets generated by RNA sequencing or mass cytometry and may serve in the future as a complementary diagnostic tool.
format Online
Article
Text
id pubmed-6317065
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley & Sons, Inc.
record_format MEDLINE/PubMed
spelling pubmed-63170652019-01-08 Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification Ijsselsteijn, Marieke E Brouwer, Thomas P Abdulrahman, Ziena Reidy, Eileen Ramalheiro, Ana Heeren, A Marijne Vahrmeijer, Alexander Jordanova, Ekaterina S de Miranda, Noel FCC J Pathol Clin Res Original Articles Checkpoint blockade immunotherapies have revolutionised cancer treatment in the last decade. Nevertheless, these are only beneficial for a small proportion of cancer patients. Important prognosticators for response to immunotherapy are the mutation burden of tumours as well as the quality and quantity of tumour‐infiltrating immune cells. High‐throughput multiplex immunophenotyping technologies have a central role in deciphering the complexity of anti‐tumour immune responses. Current techniques for the immunophenotyping of solid tumours are held back by the lack of spatial context, limitations in the number of targets that can be visualised simultaneously, and/or cumbersome protocols. We developed a tyramide signal amplification‐free method for the simultaneous detection of seven cellular targets by immunofluorescence. This method overcomes limitations posed by most widespread techniques and provides a unique tool for extensive phenotyping by multispectral fluorescence microscopy. Furthermore, it can be easily implemented as a high‐throughput technology for validation of discovery sets generated by RNA sequencing or mass cytometry and may serve in the future as a complementary diagnostic tool. John Wiley & Sons, Inc. 2018-12-04 /pmc/articles/PMC6317065/ /pubmed/30191683 http://dx.doi.org/10.1002/cjp2.113 Text en © 2018 The Authors. The Journal of Pathology: Clinical Research published by The Pathological Society of Great Britain and Ireland and John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Ijsselsteijn, Marieke E
Brouwer, Thomas P
Abdulrahman, Ziena
Reidy, Eileen
Ramalheiro, Ana
Heeren, A Marijne
Vahrmeijer, Alexander
Jordanova, Ekaterina S
de Miranda, Noel FCC
Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
title Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
title_full Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
title_fullStr Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
title_full_unstemmed Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
title_short Cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
title_sort cancer immunophenotyping by seven‐colour multispectral imaging without tyramide signal amplification
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6317065/
https://www.ncbi.nlm.nih.gov/pubmed/30191683
http://dx.doi.org/10.1002/cjp2.113
work_keys_str_mv AT ijsselsteijnmariekee cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT brouwerthomasp cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT abdulrahmanziena cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT reidyeileen cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT ramalheiroana cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT heerenamarijne cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT vahrmeijeralexander cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT jordanovaekaterinas cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification
AT demirandanoelfcc cancerimmunophenotypingbysevencolourmultispectralimagingwithouttyramidesignalamplification